Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | VENICE I: venetoclax in R/R CLL patients

Arnon Kater • 8 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Venetoclax
VENICE I

Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses the VENICE I trial (NCT02756611), a study investigating the efficacy of venetoclax in relapsed/refractory participants with chronic lymphocytic leukemia (CLL) including those with 17p deletion or tp53 mutation or those who have received a prior b-cell receptor inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Kater

Epcoritamab monotherapy before chemoimmunotherapy in Richter's transformation: Epcore CLL-1
1:48
Epcoritamab monotherapy before chemoimmunotherapy in Richter's transformation: Epcore CLL-1
Arnon Kater • 6 Dec 2025
Epcoritamab in combination with R-CHOP or lenalidomide for Richter's transformation
1:05
Epcoritamab in combination with R-CHOP or lenalidomide for Richter's transformation
Arnon Kater • 6 Dec 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater • 25 Apr 2025
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Arnon Kater • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Arnon Kater • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Arnon Kater • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Arnon Kater • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals